Evidence map›Paper›PMID 40544269›Full record

ReviewCancer cell international2025

Perspectives on NcRNAs in HBV/cccDNA-driven HCC progression.

Yang-Hsiang Lin, Ming-Wei Lai, Chau-Ting Yeh, Wey-Ran Lin

Abstract readReview
In one paragraph

Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yang-Hsiang LinLiver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
Ming-Wei LaiLiver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
Chau-Ting YehLiver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
Wey-Ran LinLiver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan. t12360@adm.cgmh.org.tw.

Funding

Chang Gung Memorial Hospital, Linkou CORPG3L0301Chang Gung Memorial Hospital, Linkou NRRPG3P0011National Science and Technology Council 113-2311-B-182A-001
6 · The paper itself

Abstract

Hepatitis B virus (HBV) integration, the HBx protein (and its mutants), and covalently closed circular DNA (cccDNA) are critical for HBV replication, packaging, and transmission to new host cells. Although nucleos(t)ide analogs (NAs) are a class of antiviral drugs that effectively suppress HBV replication, they do not eliminate cccDNA. This persistent cccDNA, often referred to as an "invisible bullet", plays a pivotal role not only in the horizontal transmission of HBV but also within the context of hepatocellular carcinoma (HCC). Growing evidence reveals that noncoding RNAs (ncRNAs) are deeply involved in cancer progression, as well as the HBV life cycle and related pathogenesis, including liver inflammation, fibrosis, and HCC. This involvement occurs through various mechanisms, as ncRNAs regulate gene transcription, act as miRNA sponges, modulate signaling pathways, and influence downstream effects. These functions depend on the proper formation of RNA structures, which are critical for maintaining the biological activity of ncRNAs. The structure of RNAs appears to play a pivotal role in their functional capacity. Moreover, both ncRNAs and viral nucleotides contribute to G-quadruplex structure formation, which is essential for the HBV life cycle and cancer progression. In this review, we provide an updated overview of the mechanisms by which key ncRNAs mediate HBV/cccDNA actions in HCC progression and focus on their roles in gene expression and structural formation/modification.

Indexed as

Cancer progressionCccDNAEpigenetic regulationG-quadruplexHBVHBxHCCNcRNAsNucleos(t)ide analogueParaspeckle

Identifiers

PMID40544269
PMCPMC12182653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.